25
Blum, D; Torch, S; Lambeng, N; Nissou, M; Benabid, AL; Sadoul, R; Verna, JM.
(2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Progress in Neurobiology., 65 (2): 135–172.
Chong ZZ, Li F, Maiese K. (2005) Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog
Neurobiol.,75(3):207–246.
Cicchetti F, Drouin-Ouellet J, Gross RE. (2009) Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?. Trends Pharmacol. Sci., 30 (9): 475–83.
Davie CA. (2008) A review of Parkinson's disease. Br. Med. Bull., 86 (1): 109–27.
De Lau LM, Breteler MM. (2006) Epidemiology of Parkinson's disease. Lancet Neurol., 5 (6): 525–35.
Goping G, Pollard HB, Adeyemo OM, Kuijpers GA. (1995) Effect of MPTP on dopaminergic neurons in the goldfish brain: a light and electron microscope study. Brain Res. 687(1-2):35-52.
Hartmann A, Hunot S, Michel PP, et al. (2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease.
Proc Natl Acad Sci U S A.,97(6):2875–2880.
Harvey BK, Wang Y, Hoffer BJ. (2008) Transgenic rodent models of Parkinson's disease. Acta Neurochir. Suppl. Acta Neurochirurgica Supplementum., 101: 89–
92.
Kalia, LV; Lang, AE. (2015) Parkinson's disease. Lancet., 386 (9996): 896–912.
Langston JW, Ballard P, Tetrud JW, Irwin I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. -02, 219 (4587): 979–
80.
Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G. (2010) Missing pieces in the Parkinson's disease puzzle. Nat. Med.,16 (6): 653–61.
Parker KL, Lamichhane D, Caetano MS, Narayanan NS. (2013) Executive dysfunction in Parkinson's disease and timing deficits. Front. Integr. Neurosci. -10, 7: 75.
26
Poli, A., Guarnieri, T., Facchinetti, F. and Villani, L. (1990) Effect of 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in goldfish brain, Brain Res., 534 45-50.
Pollard, H.B., Dhariwal, K., Adeyemo, O.M., Markey, C.J., Caohuy, H., Levine, M., Markey, S. and Youdim, M.B.H. (1992) A parkinsonian syndrome induced in the goldfish by the neurotoxin MPTP, FASEB J., 6 3108-3116.
Russell JA, Ciucci MR, Connor NP, Schallert T. (2010) Targeted exercise therapy for voice and swallow in persons with Parkinson's disease. Brain Research. 1341: 3–
11.
Samii A, Nutt JG, Ransom BR. (2004) Parkinson's disease. Lancet, 363 (9423): 1783–
1193.
Schrag A. Epidemiology of movement disorders. (edit.) Tolosa E, Jankovic JJ. (2007) Parkinson's disease and movement disorders. Hagerstown, Maryland: Lippincott Williams & Wilkins.: 50–66.
Shulman JM, De Jager PL, Feany MB (2011) Parkinson's disease: genetics and pathogenesis. Annual Review of Pathology. 6: 193–222.
Sveinbjornsdottir, S (2016) The clinical symptoms of Parkinson's disease. Journal of Neurochemistry. 139: 318–324.
Tatton WG, Chalmers-Redman R, Brown D, Tatton N (2003) Apoptosis in Parkinson’s disease: signals for neuronal degradation. Ann Neurol.; 53(Suppl 3):S61–S70.
Tressler J, Schwartz C, Wellman P, Hughes S, Smotherman M (2011) Regulation of bat echolocation pulse acoustics by striatal dopamine. J Exp Biol. 214(19): 3238-3247.
M.D., and C. David Marsden, M.D. (2000) Parkinson’s Disease: A Self-Help Guide, Marjan Jahanshahi, Demos Medical Publishing, 386 Park Avenue South, Suite 201, New York, NY 10016, (212) 683-0072.
Heiko Braak,Estifanos Ghebremedhin,Udo Rüb,Hansjürgen Bratzke,Kelly Del Tredici (2004) Stages in the development of Parkinson’s disease-related pathology.Cell Tissue Res ,October 2004 318: 121–134.
P. Damier, E.C. Hirsch, Y. Agid, A.M. Graybiel (1999) The substantia nigra of the human brain. II. Patterns of loss of dopaminergic neurons in Parkinson’s disease.
Brain, 122 pp. 1437-1448
27
Morin N., Jourdain V. A., Di Paolo T. (2014) Modeling dyskinesia in animal models of Parkinson disease. Exp. Neurol. 256 105–116 10.1016/j.expneurol.2013.01.024 Di Monte D, Sandy MS, Ekström G, Smith MT. (1986) Comparative studies on the
mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP +) cytotoxicity. Biochem Biophys Res Comm.;137:303–309.
McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. (1996) Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on
mitochondrial respiration. Biochem Pharmacol.;51:1503–1511.
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT.
(2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci.;3:1301–1306.
Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. (1999)
Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss.
Brain Res.;823:1–10.
Chun HS, Gibson GE, DeGiorgio LA, Zhang H, Kidd VJ, Son JH. (2001)
Dopaminergic cell death induced by MPP+, oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem.;76:1010–1021.
Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. (2000) The nigrostriatal dopamine system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson’s disease. J
Neurosci.;20:9207–9214.
Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin
IJ.(1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res.;1:249–254.
Langston JW, Forno LS, Rebert CS, Irwin I. (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res.;292:390–394.
Sonsalla PK, Heikkila RE. (1986) The influence of dose and dosing interval on
MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol. ;129:339–
345.
Andres-Mateos E., Mejias R., Sasaki M., Li X., Lin B. M., Biskup S., et al. (2009) Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP
(1-28
methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J. Neurosci. 29 15846–15850 10.1523,JNEUROSCI.4357-09.2009
Ungerstedt U. (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5 107–110 10.1016/0014-2999(68)90164-7
Marini AM, Lipsky RH, Schwartz JP, Kopin IJ. (1992) Accumulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in cultured cerebellar astrocytes. J
Neurochem.58:1250–1258.
Yazdani U, German DC, Liang CL, Manzino L, Sonsalla PK, Zeevalk GD. (2006) Rat model of Parkinson’s disease: Chronic central delivery of
1-methyl-4-phenylpyridinium (MPP+) Exp Neurol.;200:172–183.
Nicklas WJ, Vyas I, Heikkila RE. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-pheny-pyridine, a metabolite of the
neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci.
1985;36:2503–2508.
Ramsay RR, Dadgar J, Trevor A, Singer TP.(1986) Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the toxicity of MPTP. Life Sci.
1986;39:581–588.
Sayre LM, Wang F, Hoppel CL. (1989) Tetraphenylborate potentiates the respiratory inhibition by the dopaminergic neurotoxin MPP+ in both electron transport particles and intact mitochondria. Biochem Biophys Res Comm.;161:809–818.
Przedborski S, Jackson-Lewis V. (1998) Mechanisms of MPTP toxicity. Mov Disord.;13:35–38.
Jedediah Tressler,Christine Schwartz,Paul Wellman,Samuel Hughes,Michael (2011) Smotherman Journal of Experimental Biology,214：3238-3247; doi：10.1242 / jeb.058149
Blandini F., Armentero M.-T., Martignoni E. (2008) The 6-hydroxydopamine model:
news from the past. Parkinsonism Relat. Disord. 14(Suppl. 2), S124–S129 10.1016/j.parkreldis.2008.04.015
Rodríguez Díaz M., Abdala P., Barroso-Chinea P., Obeso J., Gonzalez-Hernandez T.
(2001) Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson’s disease. Behav.
Brain Res. 122 79–92 10.1016/S0166-4328(01)00168-1
29
Lau Y-S, Fung YK, Trobough KL, Cashman JR, Wilson JA. (1991) Depletion of striatal dopamine by the N-oxide of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Neurotoxicology.;12:189–199.
Chan P, DeLanney LE, Irwin I, Langston JW, Di Monti D. (1991) Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem.;57:348–351.
Davey GP, Peuchen S, Clark JB. (1998) Energy thresholds in brain mitochondria.
Potential involvement in neurodegeneration. J Biol Chem.;273:12753–12757.
Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. (1995) Time course and morphology of dopaminergic neuronal cell death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration.;4:257–269.
Sedelis M., Schwarting R. K. W., Huston J. P. (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson’s disease. Behav. Brain Res. 125, 109-122.
Jackson-Lewis V., Jakowec M., Burke R. E., Przedborski S. (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4, 257-269.
Schwartz C., Tressler J., Keller H., Vanzant M., Ezell S., Smotherman M. (2007) The tiny difference between foraging and communication buzzes uttered by the Mexican free-tailed bat, Tadarida brasiliensis. J. Comp. Physiol. A 193, 853-863.
30